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Plain English summary
A number of health technology assessment (HTA) organisations have developed
processes to engage patients in the assessment of new health technologies
such as pharmaceuticals, diagnostic tests, devices or medical procedures.
Typically, this involves the HTA agency providing an opportunity for patient
advocates and their patient organisations (support groups for patients with a
specific disease or condition) to provide submissions detailing experiences with
the disease and the health technology that is being assessed. While some
literature exists about how HTA agencies view the engagement of patients in the
HTA process, it is not yet clear how the patient advocates and patient
organisations themselves view this engagement. To answer this question, we
surveyed the views of patient advocates who were members of patient
organisations known to be engaged in the process of HTA or evidence-based
practice. Snowballing – that is, passing on the survey invitation from individuals
invited to take part in the survey to other individuals – occurred in one of the
countries. The responses in this country provided a very useful comparison
between the views of people who were appointed as the ‘patient
representatives’ on an HTA committee with those who contributed input as part
of the general patient organisation engagement process. Our findings identify
gaps in understanding of the purpose of patient involvement and whether
patient organisations felt their input made a difference, the information and
support provided, and if and how feedback is given to the patient organisations.
Our work can help inform further research as well as continuing improvements
in HTA patient engagement processes.
(Continued on next page)
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Abstract
Background Patient involvement in health technology assessment (HTA)
processes is becoming more frequent. However, it is not clear how patient advocates
and their disease-based patient organisations that are involved in HTA view their
involvement. We report on the results of an international survey of patient advocates
and members of patient organisations about their experiences and perceptions of that
involvement.
Methods A 16-question survey was sent out to patient advocates and members of
patient groups known to be involved in HTA processes or evidence-based practice. The
survey consisted of open-ended questions focusing on respondent characteristics, stage
and nature of involvement, support from HTA agencies for involvement, purpose of
involvement, feedback on involvement, and whether the respondents felt that their
input made a difference.
Results Of 16 individuals who received the survey, 15 responded. Three, from Italy, Israel
and Japan, were not involved in HTA in their country. Respondents from the following
countries reported involvement in HTA processes: Canada, England, Scotland, and
Wales, The Netherlands, Australia, Taiwan. The respondents indicated that HTA agencies
reach out to them either actively or passively, and that their involvement is often at the
appraisal stage of HTA. Typically, they reported involvement as either participants in
committees or providers of submissions to HTA agencies. A wide range of approaches
to supporting patient involvement by the HTA agencies was identified by respondents
– including personal and telephone support, online resources, training and provision of
information – but the level and type of support reported was uneven across
jurisdictions. Not all respondents were clear on the purpose of their involvement in HTA,
although some were able to cite specific examples of how their input made a
difference; members of an HTA decision-making committee appeared to have a better
understanding and were able to give examples. Feedback from HTA agencies to the
patient groups on their submissions is often not provided.
Conclusions Although considerable progress has been made in terms of engaging
patients and patient groups in HTA, gaps remain in how involvement is supported,
including facilitating involvement, clarity on roles, two-way flow of information, and
methods for enhancing communication between patient organisations and HTA
agencies.
Keywords: Patient involvement, Patient engagement, Patient and citizen involvement
interest group, Health technology assessment, HTA, Survey
Background
Health Technology Assessment (HTA)
Health technologies include pharmaceuticals, diagnostic tests, medical devices and
procedures. Health technology assessment (HTA) is the “systematic evaluation of
the properties and effects of a health technology, addressing the direct and
intended effects of this technology, as well as its indirect and unintended conse-
quences” [1]. This is accomplished by evaluating health technologies for their
clinical effectiveness, cost-effectiveness, safety, social and economic characteristics
[2, 3]. The aim of HTA is to make evidence-based decisions about public funding
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of health technologies e.g. by placing (or not placing) health technologies on na-
tional formularies.
Patient and public involvement in HTA
Although historically, patient and public involvement (PPI) in HTA processes and
decision-making has not been extensive, such involvement is growing internationally.
Initiatives and projects aimed at facilitating such involvement have been observed in
the United Kingdom, Europe, Canada, Asia and Australia [4–12].
Issues around patient and public involvement in HTA are often discussed under the
single umbrella of ‘PPI’, however, a distinction needs to be drawn between patients and
the public as their interests are not necessarily aligned and at times may even conflict
[13]. ‘Patients’ can be construed as (actual or potential) users or beneficiaries of a health
technology, who have experiential knowledge about a health condition to which the
health technology applies, or the health technology itself. Carers also have personal ex-
perience of living with the condition and in some instances may speak on behalf of pa-
tients. The ‘public’, on the other hand, are those members of a wider community who
have an interest in the well-being and sustainability of the health system. They have in-
sights into social aspects of HTAs but lack personal experience with the health condi-
tion or the health technology itself [13–15]. The ‘public’ is a broad category that can
include members of the general public (sometimes referred to as ‘citizens’) as well as
organisations that represent the interests of consumers as users of health care, carers
and patients themselves [12].
Two key sets of reasons for involving patients in HTA are generally cited in the lit-
erature. The first set of reasons focuses on transparency, legitimacy and fairness in de-
cision making. Patient participation is viewed as a means of enhancing trust in the
HTA decision-making process and acceptance of the resulting decisions. The second
set of reasons centres around the patients’ evidentiary contributions. Patients are seen
as contributors of valuable first-hand experiential knowledge of living with a particular
health condition; they have experience with the health technology under assessment, or
currently available technologies, the use of associated health services, and associated
benefits, risks and side effects [4, 11, 13, 15–19]. This is where the distinction between
patients and the public becomes acutely salient, as it is only the patients and possibly
their carers (but not the general public) who have this personal knowledge and are able
to provide this kind of information.
It is recognised that patient involvement can – and should – take place across the en-
tire HTA process [14]. Indeed, there is evidence that HTA agencies are increasingly in-
volving patients in all stages of HTA. A recent review of the roles of patients and the
public in HTA processes internationally, identified examples of patient involvement in
the following stages of HTA: identification of health technologies for assessment (e.g.
Australia, New Zealand, The Netherlands), priority setting or selection of technologies
for assessment (e.g. France, USA), conduct of the HTA itself (e.g. Canada, England,
Wales), review of assessment results and generation of recommendations (e.g. The
Netherlands, Germany, Canada), implementing the funding recommendations (e.g.
England, France, USA), and dissemination of the decisions (e.g. Australia, Canada)
([13]; see also [16, 19]).
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The nature of the present contribution
Patient involvement in HTA is becoming both more frequent, in that it is taking place
in more agencies or countries, and more pervasive in that it is taking place at many
stages of HTA. However, due to its relative novelty, formal examinations of the process
and impact of patient involvement in HTA are only just beginning to take place and to
be made available in journals [4].
Examinations of the HTA agencies’ initiatives often investigate PPI initiatives as a single
unit of analysis, failing to differentiate between patients and the public (e.g. [12, 19, 20]).
The analyses frequently approach PPI from the perspective of HTA agencies (e.g. [4, 12,
19, 20]), or from a mix of perspectives, combining the perspectives of HTA agencies
themselves as well as scholars, policy makers, patients, and user group members
(e.g. [17, 21]) or from the public perspective (e.g. [22]).
To our knowledge, to date no-one has focused specifically on the issue of what pa-
tient involvement in HTA looks like from the perspective of patient advocates and the
members of disease-based patient organisations (hereafter ‘patient organisations’) in-
volved in the process. It is therefore our aim to begin to fill this gap, by reporting on
the results of a survey of patient advocates and members of patient organisations
known to be involved in the HTA process about their experiences and perceptions of
their involvement in the HTA processes. In particular, the purpose of the present re-
search was to identify issues faced by patient advocates when making submissions to an
HTA agency, either as part of the patient support group or as individuals.
Methods
The questionnaire was jointly designed by the authors, representing extensive experi-
ence in processes of HTA both as a consumer representative and committee member
(JW), and as an academic experienced in preparing HTAs and a member of HTA com-
mittees and HTAi’s Ethics Interest Group (AMS). The authors also have broad experi-
ence through membership of the Patient and Citizen Involvement in HTA Interest
Group, with one (JW) being the Group’s former Chair.
The questionnaire was informed both by the existing literature in this area and the
professional experience of the authors. The included questions were selected to align
with the study objectives – to query issues specifically applicable to patient advocates
and disease-based patient organisations (as opposed to HTA agencies, the public, in-
dustry, or researchers involved in HTA). The emphasis was on use of simple language,
as it was anticipated that the survey would be completed by an international audience.
The questionnaire asked 16 questions, focusing on respondent characteristics, stage
and nature of involvement, support from HTA agencies for involvement, purpose of in-
volvement, feedback on input given, and whether the respondents felt that their input
made a difference. All of the questions were open-ended in order to avoid suggesting
any specific responses and to give the respondents an opportunity to explain their an-
swers in-depth and in their own words. Examples were provided in the questionnaire
where appropriate in order to facilitate providing answers. A copy of the questionnaire
is provided in the Appendix.
Purposive sampling was applied to select respondees who could provide detailed and
relevant information. The questionnaire, together with an introductory letter, was sent
by e-mail to the selected international patient advocates on 14 March 2016. The
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recipients were selected on the basis of their interest in joining the HTAi Patient and
Citizen Involvement Patient Panel, having worked with or as members of the HTAi Pa-
tient and Citizen Involvement in HTA Interest Group, or as being part of the Cochrane
Collaboration Consumer Network and likely to be involved in evidence-based health
care and therefore HTA. The recipients were asked to complete the questionnaire by 4
April 2016. To maximise the response rate, if the recipient felt unable to respond to
the questionnaire, either because of the timeframe or if there was someone in their or-
ganisation or a related organisation who would be more able to do so, they were asked
to forward the e-mail to that person. The recipients were also sent up to three re-
minders about the questionnaire, where necessary, in order to maximise the response
rate.
Unexpectedly, snowballing of responses occurred in one of the countries (Canada) –
the survey invitation was passed on by the original recipient to fellow ‘patient represen-
tatives’ on an HTA appraisal committee. This has led to this country having a high
proportion of the total responses. It did, however, provide a very useful comparison be-
tween the views of ‘patient representatives’ who were appointed in that capacity as
members of an HTA committee, with those of patients who contributed input into
HTAs through their disease-based patient organisations.
The responses were succinct and thematically summarised by one of the authors.
The analysis was checked by the second author and fed back to the respondents. The
respondents were advised that as no personal or private data was being collected, a for-
mal ethics approval was not required. Nevertheless, ethical practices for survey research
were followed in that respondents’ anonymity was ensured and sufficient information
was provided about the survey and its authors, to enable respondents to make an in-
formed decision about participating. Respondents were informed that a return of a
completed questionnaire implied a free and informed consent to share the information
publicly.
Results
Profile of the respondents
Of the 16 individuals who received the survey, 15 responded. Countries represented by
the respondents include: Canada, England, Scotland, and Wales, The Netherlands,
Australia, Taiwan, Japan, Italy and Israel (Table 1). Despite several attempts, the authors
were unable to obtain a response from Germany.
Respondents from three countries (Italy, Israel, Japan) stated that they do not con-
tribute to HTA activities in their country. This does not mean, however, that there is
no patient involvement in any HTA activities in these countries, for example at a hos-
pital level. The remainder of the article focuses on the responses received from:
Canada, England, Scotland, and Wales, The Netherlands, Australia, Taiwan.
How are the patient organisations reached, when, and what is their role
The respondents identified two main approaches adopted by the HTA agencies to
reach out to patients and/or patient organisations (Table 2). First, the agencies contact
the patient organisations that are registered with them, seeking submissions when a
relevant health technology is being assessed. The second approach consists of agencies
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posting requests for submissions on the agency’s website and waiting for responses
from patients, where applicable, and patient organisations (or the public).
As seen in Table 2, patient advocates reported patient organisation involvement at
various stages of the HTA process. However, this was predominantly at the appraisal
stage, when the accumulated scientific and economic evidence about a technology is
formally assessed by an HTA committee and contextualised against social and ethical
issues. Less often, patient organisation participation was sought at the scoping stage to
outline how the technology is to be assessed, or at a consultation stage in response to
an HTA committee’s recommendations.
The types of involvement varied, although provision of submissions predominated.
Patient organisations in all of the countries represented by the patient advocates
responding to our survey reported this type of involvement in HTA. Additionally, pa-
tient advocates reported involvement of their organisations through provision of com-
ments on recommendations, provision of patient experts to the HTA agency, and
participation in hearings or meetings.
Support for ‘patient representatives’ and patient groups involved in HTA
‘Patient representatives’ (as designated by the HTA agency concerned) on an HTA commit-
tee reported receiving a wide range of support from HTA agencies. The support included:
a dedicated staff person at the HTA agency, provision by the HTA agency of orientation,
Table 1 Profile of respondents to the questionnaire
Country Number of
respondents
Respondent type HTA agencies the respondents are
involved withPatient
representative on
HTA agency’s
committee
Member of a patient
group [that potentially
submits to an HTA
agency]
United
Kingdoma
2 – 2 The National Institute for Health and
Care Excellence (NICE); Scottish
Medicines Consortium (SMC); All
Wales Medicine Strategy Group
(AWMSG); Various (rare diseases
focus)
The
Netherlands
1 – 1 Zorginstituut Nederland (ZIN, The
National Health Care Institute)
Canadaa 6 3 3 Canadian Agency for Drugs and
Technologies in Health (CADTH)
Common Drug Review (CDR); Pan-
Canadian Oncology Drug Review
(pCODR), Canadian Agency for Drugs
and Technologies in Health (CADTH)
Australiaa 1 – 1 Pharmaceutical Benefits Advisory
Committee (PBAC); Medical Services
Advisory Committee (MSAC)
Taiwan 2 – 2 The National Health Insurance
Administration (NHIA);
Pharmaceutical Benefits and
Reimbursement Scheme (PBRS)
Japan 1 – 1 None
Italy 1 – 1 None
Israel 1 – 1 None
aSome respondents indicated involvement with more than one agency
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online resources, webinars, monthly teleconferences, and supported attendance at annual
symposia. Patient advocates involved with disease-based patient organisations reported that
some (although not all) HTA agencies dedicate a staff member as contact person or have a
dedicated PPI team. Other approaches reported include: HTA agencies offering guidance
or framework documents (either via e-mail or on the agency’s website), arranged meetings
with patient organisations to provide guidance and information, and facilitating contact be-
tween patient organisations to enable peer support (Table 3).
Formal training was not often provided by HTA agencies to patient organisations, al-
though some patient advocates reported that webinars are provided. Others reported that
training is provided by industry and other (e.g. academic) organisations; training also takes
the form of mentoring amongst the members of the patient organisations themselves.
Patient organisations often do not receive information about the technology under
assessment from the HTA agency itself but, rather, rely on a wide range of other
sources for that information. Those sources include: publicly available data, industry,
participants in clinical trials or clinical trial staff, other members of the patient
Table 2 How are the patient groups identified, in what role are they involved, and when
(at what stage)
Country How does the agency
reach out to patient
groups?
Stage of HTA at which the
patient representatives or
patient groups are
involved?
How are the patient
representatives or patient groups
involved in the HTA?
Scotland (SMC) • Patient group is registered
with the HTA agency, and
notified by the HTA
agency
• Appraisal stage • Provide submission to the agency
•
Participate in meetings of patient
groups, clinicians, agency
England and
Wales (NICE,
AWMSG, rare
diseases)
• Patient group is registered
with the HTA agency, and
notified by the HTA
agency
• At scoping stage,
stakeholders are asked to
recommend patients [or
patient groups
• Through disease registry,
newsletters or social
media
• Scoping stage workshop
• Appraisal stage
• Appeals of
recommendations
• Scientific advice stage
• Provide patient experts who
participate in workshops or
committee meetings
• Provide submission to the agency
The
Netherlands
(ZIN)
• Patient group is registered
with the HTA agency
• HTA agency reaches out
to umbrella groups
• Appraisal stage • Provide submission to the agency
• Provide a statement at public
meetings
Canada (CADTH
CDR and
pCODR)
Patient representatives
Patient groups
• Patient group is registered
with the HTA agency, and
notified by the HTA
agency
HTA agency posts on its
website a call for
submissions by patient
groups
• Unclear answer (when
submission goes to
committee)
• As members of an HTA
committee
• Provide comments on draft
recommendations (patient
groups)
Provide submissions to the agency
(patient groups)
Australia (PBAC,
MSAC)
• No answer provided, learn
from industry
• Appraisal stage • Provide submission to the agency
• Hearings
Taiwan (NHIA,
PBRS)
• Users registered online
• HTA agency posts on its
website a call for
submissions by patients,
groups
• Unclear • Patient representatives attend
committee meetings
• Provide short submission to the
agency
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Table 3 Support for patient representatives and patient groups involved in HTA
Country What kind of support and
guidance is offered by the
agency?
What kind of training is
offered by the agency?
What kind of information on
the health technology is
provided, and by whom?
Scotland
(SMC)
• Guidance offered by agency’s
Patient and Public
Involvement team
• Guidance documentation
exists
• A clear framework for
submission of input is
provided on the agency
website
• Individuals participating in
the process are greeted and
briefed
• Peer support is provided –
group can contact other
patient groups with
experience in process
• Has Public Involvement
Network Advisory Group
Training and capacity
building, ad hoc or yearly
• A form (recently revised by
patients together with
pharmaceutical industry) with
information is provided
England and
Wales (NICE,
AWMSG, rare
diseases)
• Guidance offered by agency’s
Public Involvement team
• Contact person is provided
• Guidance documentation
exists and is sent out
• Individuals participating in
the process are greeted and
briefed
• A clear framework for
submission of input is
provided on the agency
website
• Peer support is provided –
group can contact other
patient groups with
experience in submissions/
process
• Contact team exists but is
not yet well established
• No formal contact is provided
• Support is provided for key
group personnel
• Training and capacity
building, ad hoc or yearly
• Training is provided for
patient groups but it is not
specific for patient groups
and not regular
• No
• During scoping stage,
background is provided on
the drug
• It is assumed we know about
the treatment but we can
request further information
• It is possible to request
information but no formal
mechanism for this exists
• The information is very
limited – from clinical trials; if
a patient has been in a
relevant trial, the group
obtains information from that
patient
The
Netherlands
(ZIN)
• No support is provided
• A guidance document exists
but requires updating
• No • The group utilises whatever
information its patients or
umbrella organisation has
• The media
Canada
(CADTH CDR
and pCODR)
Patient representatives on HTA
Committees
• Orientation is provided
• Topic orientated speakers
• Online resources and sent
materials
• Monthly teleconference
• Attendance at annual
symposium
Patient groups(provide input
and/or feedback)
• Online guidance and
information
• Agency has a contact person
to answer questions
• Has a patient advisory group
(Patient Community Liaison
Forum)
• Training in HTA
• Training through group
coursesa
• Webinars are provided
• No formal training;
mentoring is done within
the patient group itself
• Obtain information from the
drug company
• Obtain information from
patients who have
participated in clinical trials or
are waiting for access
• From conferences, journal
articles
Scott and Wale Research Involvement and Engagement  (2017) 3:2 Page 8 of 17
organisation itself, the media, internet searches, pharmacists, doctors, other patient or-
ganisations, existing HTA reports, conferences or patient symposia. Where agencies do
provide information, their approaches include: provision of background and key infor-
mation using a pre-designed form for the industry sponsor to complete; or the agency
enables patient organisations to request further information from the HTA agency if
required.
Purpose, outcomes and feedback on the involvement
The understanding of the purpose of patient involvement in HTA varied among the re-
spondents. Some respondents reported that the purpose was unclear to them, or that it
was only somewhat clear; one respondent felt that patient involvement was an exercise
in ‘ticking a box’. However, others understood patient involvement as an opportunity to
provide HTA agencies with information on the experience of living with a condition or
using existing treatments and the treatment under assessment. The patients can pro-
vide information on the value and impact of the treatment from a patient perspective,
to help agencies understand unmet needs, provide input more generally, or help to set
the content of a health insurance package (Table 4).
In response to the question whether their input made a difference, a mixed picture
emerged. Some respondents did not provide an answer or felt that their input has not
made a difference for some time. Others cited a variety of ways in which their input
has made a difference to the HTA process. ‘Patient representatives’ on HTA commit-
tees were able to point to specific funding decisions, for example, a decision to fund a
drug due to information on improvement in quality of life, and identification of sub-
groups that were particularly negatively impacted by the disease. Responses from pa-
tient organisations were more general, and focused on the areas where they felt their
input has made a difference, such as: contextualising the quality of life data from trials,
illustrating unmet need, clarifying the impact on daily life of the disease or health tech-
nology, helping to educate HTA personnel about the disease or its treatment, and help-
ing to create a fuller evidentiary picture by adding to industry and clinician evidence.
Some patient advocates noted that either the impact or the weight of their submissions,
vis-à-vis the other evidence considered, is unclear.
Table 3 Support for patient representatives and patient groups involved in HTA (Continued)
Australia
(PBAC, MSAC)
• No clear guidelines • No • The group is informed by the
industry
• Search for clinical trial data on
our own
Taiwan (NHIA,
PBRS)
• Brief guidance provided on
the agency’s platform
• Meeting with patient groups
to discuss involvement and
provide information and
guidance
• Training provided by
International Research
Based Pharmaceutical
Manufacturers Association,
Taiwan Association of
Patient Organisations,
• Training is provided by
Taiwan Society for
Pharmacoeconomics and
Outcome Research
• Information is sought from
pharmacists, doctors, patient
groups and monthly
symposia for patients
• Information is sought from
clinical trial staff in hospital,
trial patients, patient
organisations; HTA report;
International organisations for
relevant disease area,
pharmaceutical companies
ainformation provided by ‘patient representatives’ sitting on an HTA agency’s committee, and members of the patient
groups submitting to an HTA agency, is separated out for clarity
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Feedback is often not formally provided by the HTA agencies, and one respondent
noted that this makes it difficult to know the value of the submission. However, some
respondents reported that it can be gleaned whether the patient organisation
Table 4 Purpose, outcomes and feedback on the involvement
Country Is the purpose of patient
involvement clear, and if so,
can you say what it is?
Does the input you provide
make a difference, and if so,
can you provide an example?
Does the HTA agency provide
any feedback on how the
patient group information was
used and incorporated into
decisions?
Scotland
(SMC)
• To ensure appraisal
committees understand
impact of new drugs on
quality of life; human
perspective; patient
experience of condition and
treatment needs
• Weighting and impact [of
input] not clear.
• Help to create the ‘whole
picture’ together with the
industry and clinician
information
• Contact with advocacy
groups of 1.5 years has led to
being listened to, arguments
heard
• Group is advised of the
decision but no feedback is
provided
• Final reports or documents
reference key points from
patients, carers
England and
Wales (NICE,
AWMSG, rare
diseases)
• To ensure appraisal
committees understand
impact of new drugs on
quality of life; human
perspective; patient
experience of condition and
treatment needs
• Learning still – unclear
• Weighting and impact [of
input] not clear.
• Worked with company,
clinicians to provide patient
access scheme to increase/
show value
• Contact with advocacy
groups of 1.5 years has led to
being listened to, arguments
heard
• Group is advised of the
decision but no feedback is
provided
• Final reports or documents
reference key points from
patients, carers
• Feedback is provided from
meetings but may not be
able to share it with the rest
of the patient group
The
Netherlands
(ZIN)
• Sets the content of the
insurance package, like G-
BAZIN
• None since the Pompe, Fabry
diseases example
• No, communicated through
industry
Canada
(CADTH CDR
and pCODR)
Patient representatives
• It should be clear: the
experience of living with [a
disease], treatments
• Where value lies from the
patient’s perspective,
experience
Patient groups
• Yes – to give input
• To hear from patients,
check a box
Somewhat – to understand
impact on patients, fill unmet
need
• It does make a difference.
One drug was funded based
on submission documenting
how life was improved on
treatment; identified relevant
subgroup negatively affected
by [a disease]
• Importance of single
measures/associated
symptoms on daily life;
relevance of quality of life
data from clinical trials;
unmet need in a patient
subgroup
• It demonstrates the impact
on daily life, careers, finances,
vision of life of carers in
relation to quality adjusted
life years
• In drafting final
recommendations
• In final recommendations
Educate committee about
disease, available drugs and
use, intolerability
• Patient submissions are
referenced in both interim
and final recommendations
(reports) on agency’s website
• Groups know their feedback
is considered if a detail is
queried
• No information on how it is
used, its value
• Not yet
Yes (no further detail
provided), feedback
Australia
(PBAC)
• Unclear • No example provided • No
Taiwan
(NHIA, PBRS)
• Providing input, collecting
patients’ opinions
• No answer provided • An e-mail is sent acknow-
ledging the submission
• Submission is listed in the
meeting minutes
• No direct feedback is
provided
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submission was utilised, for example, by examining the meeting minutes to see if the
submission is listed, or examining the interim and final recommendations (whether
they make reference to patient organisation submissions or are changed following com-
ment by the patient organisation). Where an agency queries the patient organisation
about the content of their submission, it can also be inferred that the submission is be-
ing considered by the HTA agency. One respondent noted that feedback was provided
(that their submission had been received) but did not furnish any details.
Discussion
A mixed picture thus emerges about patient involvement in HTA from the perspective
of patient advocates involved in the process. Patient advocates and ‘patient representa-
tives’ report that HTA agencies involve patient organisations either actively, by reaching
out to groups known to them (e.g. those listed in the HTA agency’s database), or pas-
sively by posting requests for input on the agency’s website. The passive approach has
the drawback of placing the onus on the patient organisation to monitor the agency’s
website for HTAs relevant to its members, or to be informed by industry. The active
approach – HTA agency reaching out to patient organisations – means that patient or-
ganisations know when their input is being sought, and they can then notify their
members. The HTA agencies using the active approach are generally open to adding
patient organisations to their databases, although some have criteria that need to be
met. Communication between patient organisations involved in similar or overlapping
disease areas would also be beneficial, as this could further increase patient participa-
tion in the HTA process. Additionally, agencies may consider proactive advertising,
since patient organisations may not necessarily be representative of patient populations
in all cases.
Approaches to supporting disease-based patient organisation involvement in the
HTA process include both personal and electronic means. Personal support involves
dedicating an HTA agency staff member or team, enabling in-person meetings of pa-
tient organisations with HTA agencies, or facilitating interactions between patient orga-
nisations. Online approaches include provision of guidance or other documents (either
via e-mail or by posting them on the agency’s website). Our questionnaire did not query
which of these approaches is preferable to the patient organisations. It is possible that
the answer to this question would vary by jurisdiction, HTA agency, and patient organ-
isation. It could also depend on the size, remit and capacity of both the HTA agency
and the patient organisation. Therefore, clear communication between the agency and
patient organisations is of crucial importance. Individual agencies and patient organisa-
tions could benefit from considering approaches used by other agencies.
Questions about training for patients and patient organisations revealed that patients
participating in HTA committees as ‘patient representatives’ receive training from the
HTA agency. However, such training may not be provided by HTA agencies to patient
organisations. Patient organisations may therefore turn to industry or other organisa-
tions, or facilitate internal mentoring within their own groups. This is less than ideal,
as HTA agencies are best positioned to advise patient organisations about agency-
specific processes and informational needs. Extending the training that is provided to
‘patient representatives’ on HTA committees to patient organisations and others could
be a worthwhile endeavour.
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A similar point can be made about information provision by HTA agencies to patient
organisations. Although patient advocates report a wide range of creative approaches to
obtaining information about technologies under assessment, the HTA agency or the in-
dustry sponsor for the new technology is in the best position to provide this informa-
tion to patient organisations. Issues arise around confidentiality of the data provided to
the agency, and codes of conduct created by overarching pharmaceutical company bod-
ies to protect patients from direct advertising. An approach adopted in Scotland – of
providing patient organisations with standardised information obtained using a form
that has been co-designed by industry and patients and is completed by industry – may
be worthwhile for adopting in other jurisdictions. Beyond that, initiatives reported in
the literature around public involvement in HTA may also be helpful in terms of pa-
tient involvement in HTA. These include: providing patients participating in HTA com-
mittees with a clear and detailed description of the role, and preparing introductory
documents about HTA and HTA agency processes for the involvement of patients and
patient organisations together with other background and guidance materials [10, 23].
Although respondents provided a range of answers about the purpose of patient
involvement in HTA, it was somewhat surprising that some of the respondents –
involved in disease-based patient organisation submissions to HTA agencies – report a
lack of clarity about the purpose of such involvement. This may point to
informational needs by patient organisations that go beyond the need for informa-
tion about the specific health technologies. This could include: the need for infor-
mation about HTA itself and its goals in that jurisdiction; the process and
methods adopted by the specific agency; the types of information and evidence
considered during the technology assessment; and the specific role that information
provided by patient groups plays. The last of these needs clarification as several re-
spondents noted that the weight or impact of the patient submissions, vis-à-vis
other evidence considered in the HTA process, was unknown to them. Providing
this information could, moreover, help to resolve the identified lack of clarity about
whether the information provided by the patient organisations makes a difference
to the HTA processes and outcomes. Unsurprisingly, ‘patient representatives’ par-
ticipating on HTA committees are better equipped to cite specific examples where
patient submissions made a difference as they are part of the decision-making pro-
cesses and so have first-hand experience of the discussions that take place. The pa-
tient advocates working with patient organisations were less able to do so, and
answered the question by focusing on the type of input they felt made a difference
(e.g. on daily experience with the disease, impact on quality of life).
Patient advocates with patient organisations report that although they can sometimes
identify whether their submission has been utilised, feedback on the submissions is
generally not provided to them by the HTA agencies. This is problematic as one of the
dominant types of patient organisation involvement in the HTA process takes the form
of written submissions, which is a resource intense activity for patient organisations.
Feedback could inform the value of using those resources and additionally lead to di-
rected quality improvements in submissions. HTA agencies are best positioned to iden-
tify their own informational needs and how the information provided was used by
them [4]. CADTH in Canada (Common Drug Review) does now provide feedback to
the patient organisations that make submissions, and has a policy of making the
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submissions easily accessible on its website, where it is given permission to do so, so
that other patient organisations can learn from them [24]. SMC in Scotland also gives
examples of useful submissions on their website so that other groups can learn from
them and their PPI team will review submissions that are in preparation [25].
The challenges around involvement in HTA that were identified by patient advo-
cates and their disease-based patient organisations when responding to our ques-
tionnaire are not surprising. Many of these same challenges to PPI have been
identified by HTA agencies themselves. According to HTA agencies, some of the
challenges include: tensions between scientific healthcare evidence and social con-
siderations when considering the patient perspective; practical issues around en-
gaging patients; dissemination of information to patient organisations; inadequate
time to conduct high-quality engagement activities; the potential for lengthening
the process of HTA by involving patients; lack of expertise in qualitative research
within HTA agencies; how to address the diversity of patient populations, and
identifying participants who are truly ‘representative’; and absence of resources,
both within HTA agencies and patient organisations, to carry out meaningful en-
gagement [19]. The picture that emerges from the present questionnaire is that a
wide range of approaches have been adopted by HTA agencies to address some of
these challenges. It is therefore hoped that some of the approaches identified here
can serve as examples of the way forward both for HTA agencies and disease-
based patient organisations. This may be particularly relevant to HTA agencies that
have yet to involve patients or are in the early stages of involvement.
Limitations and strengths
The questionnaire’s strength lies in its very high response rate (94%), which is consider-
ably higher than the rates typically reported in the surveys conducted in the field of
HTA of from 18–90% [12, 19, 20, 26]. The high response rate is attributable to many of
the respondents being known to one of the authors (JW), who personally reached out
to the respondents. However, it needs to be noted that – being the first survey focusing
on the views of patient organisations and patient advocates – the survey was consider-
ably smaller than other surveys in HTA, which also limits its generalisability. Another
strength lies in the profile of respondents, which allowed us to compare the perspec-
tives of patient advocates working within disease-based patient organisations involved
in the HTA process with the views of ‘patient representatives’ who are members of the
HTA committee.
A limitation lies in the potential for selection bias in the recruited sample of par-
ticipants as the survey specifically targeted people known to be involved in HTA in
their own countries. This targeting was deliberate, however, as the present survey
was intended to identify the views of those patient advocates and patient organisa-
tion members known to have experience with HTA processes; it was not an effort
to assess the awareness of patient advocates around HTA activities in their own
countries, which will become the main focus of a future, more broadly distributed
questionnaire.
It is worth noting that because more than half of the responses were from
Canada and UK (in aggregate), the views presented here are of some of the most
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developed patient involvement initiatives, in terms of both longevity and compre-
hensiveness, and may not be representative of the views of patients and disease-
based patient organisations involved in HTA processes in other jurisdictions.
Identifying approaches to patient involvement in jurisdictions with more developed
patient involvement initiatives does, however, offer an opportunity to those jurisdic-
tions with less developed initiatives to identify options that can be adapted and
adopted in their countries.
Finally, a potential limitation lies in the open-ended nature of the questions used in
the survey, which may have led to their incorrect interpretation by non-English as first
language speakers. To address this, a summary of the responses was sent to the respon-
dents for their verification. Some adjustment in the wording of the summary was made
in response to arguments presented to us by the ‘patient representatives’ on an HTA
appraisal committee. This was related to patient organisations being able to give sug-
gestions on draft recommendations and see changes in wording, which the ‘patient rep-
resentatives’ saw as feedback on the patient organisation submissions. Otherwise, we
are confident that the potential for this problem was minimised.
Conclusions
The findings of this questionnaire suggest a mixed picture. Some progress has been
made in terms of engaging patients through their disease-based patient organisa-
tions in the HTA process, in a way that is sensitive and appropriate to patient or-
ganisation needs. However, important gaps remain. Therefore, the next steps could
include a careful consideration of an optimal balance between enhancing the op-
portunities for patient organisations to make contributions to HTA and the infor-
mational and process needs of the HTA agencies. Among the specific issues in
need of consideration, are:
 What are the best processes for facilitating the involvement of disease-based patient
organisations in HTA;
 How should patient organisation involvement be operationalised, e.g. what role(s)
should patients take on, what training do the patient organisations need to enable
this;
 How to enhance communication between HTA agencies and patient organisations
vis-à-vis the purpose of involvement, processes, and expectations;
 How best to support the involvement of patient organisations in HTA, what types
of ongoing training and quality improvement, information provision, feedback
processes, etc., should be implemented.
As suggested by the questionnaire, patient involvement processes are constantly
evolving and some agencies have already taken steps towards addressing at least
some of the identified issues. Patient organisations recognise and appreciate those
efforts. It is hoped that the findings presented here will continue to spur efforts to-
wards further developments by these and other HTA agencies. A re-survey is
planned in the future, this time co-designed with the patient members and patient
group representatives.
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